Second, fenofibrate can be administrated via the oral route, which is more acceptable to patients and can avoid clinical risks of endophthalmitis or retinal detachment associated with intravitreal injections.51 Third, anti-VEGF antibodies are expensive, while fenofibrate is cost-effective, having the potential to reduce the economic burden of patients. The gene discussed is VEGFA; the disease is endophthalmitis.